Immunostimulatory neem leaf preparation acts as an adjuvant to enhance the efficacy of poorly immunogenic B16 melanoma surface antigen vaccine

International Immunopharmacology

Volumn 5, Issue 7-8, 2005, Pages 1343-1352

  Baral, Rathindranath ^a   Mandal, Ishita ^a   Chattopadhyay, Utpala ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

Adjuvant; B16Melanoma; Immunity; Neem leaf preparation; Vaccine

Indexed keywords

AZADIRACHTA INDICA EXTRACT; B 16 MELANOMA SURFACE ANTIGEN VACCINE; FREUND ADJUVANT; IMMUNOGLOBULIN G1; MELANOMA VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; AZADIRACHTA INDICA; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN LYMPHOCYTE; TUMOR GROWTH; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; AZADIRACHTA; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; IMMUNIZATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PLANT LEAVES; PLANT PREPARATIONS;

EID: 19444373115     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2005.03.008     Document Type: Article

References (36)

1. S. Stevanovic Identification of tumor associated T-cell epitopes for vaccine development Nat Rev, Cancer 2 2002 514 520
2. P.F. Robbins, and Y. Kawakami Human tumor antigens recognized by T cells Curr Opin Immunol 8 1996 628 633
3. M.L. Disis, F.M. Shiota, and M.A. Cheever Human her-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for "self" tumor antigens Immunology 93 1998 192 199
4. M. Bhattacharya-Chatterjee, R.N. Baral, S.K. Chatterjee, R. Das, H. Zeytin, and M. Chakraborty Counterpoint cancer vaccine: single epitope anti-idiotype vaccine versus multiple epitope antigen vaccine Cancer Immunol Immunother 49 2000 133 141
5. F.M. Audibert, and L.D. Lise Adjuvants: current status, clinical perspective and future prospects Immunol Today 15 1993 281 284
6. K. Dredge, J.B. Marriott, S.M. Todryk, and A.G. Dalgleish Adjuvants and promotion of Th1-type cytokines in tumor immunotherapy Cancer Immunol Immunother 51 2002 521 523
7. C.R. Kensil, U. Patel, M. Lennick, and D. Marciani Separation and characterization of Saponins with adjuvant activity from Quillaja saponaria Molina Cortex J Immunol 146 1991 431 437
8. Y. Kawarada, R. Ganss, N. Garbi, T. Sacher, B. Arnold, and G.J. Hammerling NK- and CD8(+) T cell mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides J Immunol 167 2001 5247 5253
9. G.B. Lipford, M. Bauer, C. Blank, R. Reiter, H. Wagner, and K. Heeg CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen-a new class of vaccine adjuvants Eur J Immunol 27 1997 2340 2344
10. D.M. Klinman, A.K. Yi, S.L. Beaucage, J. Conover, and A.M. Krieg CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon-γ Proc Natl Acad Sci U S A 93 1996 2879 2883
11. G.J. Weiner, H.M. Liu, J.E. Wooldridge, C.E. Dahle, and A.M. Krieg Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization Proc Natl Acad Sci U S A 94 1997 10833 10837
12. J.W. Steiner, B. Langer, and D.L. Schatz The local and systemic effects of Freund's adjuvant and its fractions Arch Pathol 70 1960 424 428
13. J.C. Cox, and A.R. Coulter Adjuvants: a classification and review of their modes of action Vaccine 15 1997 248 256
14. K.A. Foon, M. Chakraborty, W.J. John, A. Sherratt, H. Kohler, and M. Bhattacharya Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine J Clin Invest 96 1995 334 342
15. K.A. Foon, J. Lutzky, R.N. Baral, J.R. Yannelli, L. Hutchins, and A. Teitelbaum Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2 J Clin Oncol 18 2000 376 384
16. P.O. Livingston, G.Y.C. Wong, and S. Adluri Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside J Clin Oncol 12 1994 1036 1044
17. R.N. Baral, A. Saha, S. Chatterjee, K.A. Foon, A.M. Krieg, and G.J. Weiner Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen Cancer Immunol Immunother 52 2003 317 327
18. J. Fagerberg Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy Med Oncol 13 1996 155 160
19. J. Stritzke, T. Zunkel, and J. Stteinmann Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model Br J Haematol 120 2003 27 35
20. K. Biswas, I. Chattopadhyay, R.K. Banerjee, and U. Bandyopadhyay Biological activities and medicinal properties of neem (Azadirachta indica) Curr Sci 82 2002 1336 1345
21. G.V. Satyavati M.K. Raina M. Sharma Medicinal Plants of India vol. 1 1976 Indian Council of Medical Research New Delhi 363 365
22. Neem: a tree for solving global problems. National Research Council, Washington, DC: National Academic Press 1992.
23. A. Ray, B.D. Banerjee, and P. Sen Modulation of humoral and cell mediated immune responses by Azadirachta indica (neem) in mice Indian J Exp Biol 34 1996 698 701
24. S.N. Upadhyay, S. Dhawan, S. Garg, and G.P. Talwar Immunomodulatory effects of neem (Azadirachta indica) oil Int J Immunopharmacol 14 1992 1187 1193
25. U. Thatte, and S. Dahanukar Rasayana concept: clues from immunomodulatory therapy S.N. Upadhyay Immunomodulation 1st ed. 1997 Narosa Publising House New Delhi 141 148
26. R.N. Baral, and U. Chattopadhyay Neem (Azadirachta indica) leaf mediated immune activation causes prophylactic growth inhibition of murine Ehrlich carcinoma and B16 melanoma Int Immunopharmacol 4 2004 355 366
27. Haque E, Mandal I, Pal S, Baral RN. Prophylactic dose of neem (Azadirachta indica) leaf preparation restricting murine tumor growth is nontoxic, hematostimulatory and immunostimulatory. Immunopharmacol Immunotoxicol [in press].
28. D. Xu, P. Gu, P.Y. Pan, Q. Li, A.I. Sato, and S.H. Chen NK and CD8 + T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation Int J Cancer 109 2004 499 506
29. S. Pal, U. Sanyal, and U. Chattopadhyay Purification and characterization of a new 85-kDa glycoprotein antigen from human breast tumor Int J Cancer 60 1995 759 765
30. R.N. Baral, A. Sherrat, R. Das, K.A. Foon, and M. Bhattacharya-Chatterjee Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human HER-2/Neu Int J Cancer 92 2001 88 95
31. A. Chakraborty, N.G. Chakraborty, and U. Chattopadhyay Prolactin responses of NK cells, but not LAK cells is deficient in patients with carcinoma of oral cavity and during aging Int J Cancer 66 1996 65 69
32. D. Yadav, and G.K. Khuller Evaluation of immune responses directed against 30kDa secretory protein of mycobacterium tuberculosis H37Ra complexed in different adjuvants Indian J Exp Biol 39 2001 1227 1234
33. D. Herlyn, M. Herlyn, and Z. Steplewski Monoclonal antibodies in cell mediated cytotoxicity against human melanoma and colorectal carcinoma Eur J Immunol 9 1979 657 661
34. K. Horvathova, A. Vachalkova, and L. Novotny Flavonoids as chemopreventive agents in civilization diseases Neoplasma 48 2001 435 441
35. Y. Jiao, J. Wen, and X. Yu Influence of flavonoid of Astragalus membranaceus's stem and leaves on the function of cell mediated immunity in mice Zhongguo Zhong Xi Yi Jie He Za Zhi 19 1999 356 358
36. N. Nair, S. Mahajan, R. Chawda, C. Kandaswami, T.C. Shanahan, and S.A. Schwartz Grape seed extracts activates Th1 cells in vitro Clin Diagn Lab Immunol 9 2002 470 476